Peer Reviewed
Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.
Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Articles by Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Metformin Cuts Long COVID Risk by 50%, New Trial Confirms
2
Phase 3 MonumenTAL-3 Trial Demonstrates Significant Survival Benefit With Talquetamab-Based Regimens in Relapsed/Refractory Multiple Myeloma
3
Combined Food Policies, Including Labeling and Advertising Bans, Plausibly Reduce Childhood Obesity
4
Halfway There Is Nowhere
5